ERYTHROPOIETIN ANALOG-IgG FUSION PROTEINS
First Claim
Patent Images
1. An EPOa-IgG fusion protein, wherein at least one amino acid residue of the EPOa moiety of the fusion protein is altered such that a site which serves as a site for glycosylation in EPO does not serve as a site for glycosylation in EPOa.
5 Assignments
0 Petitions
Accused Products
Abstract
Erythropoietin analog-human IgG fusion protein (EPOa-IgG) fusion protein and methods of making and using the fusion protein.
-
Citations
61 Claims
- 1. An EPOa-IgG fusion protein, wherein at least one amino acid residue of the EPOa moiety of the fusion protein is altered such that a site which serves as a site for glycosylation in EPO does not serve as a site for glycosylation in EPOa.
-
3-4. -4. (canceled)
-
7. (canceled)
-
15-19. -19. (canceled)
-
21-26. -26. (canceled)
-
27. An isolated nucleic acid comprising a nucleotide sequence which encodes an EPOa-IgG fusion protein, wherein at least one amino acid residue of the encoded EPOa-IgG which can serve as a glycosylation site in EPO is altered such that it does not serve as a glycosylation site in EPOa.
-
28-32. -32. (canceled)
-
33. A method of making an EPOa-IgG fusion protein comprising:
-
providing a transgenic organism which includes a transgene which directs the expression of the EPOa-IgG fusion protein; allowing the transgene to be expressed; and
,recovering the EPOa-IgG fusion protein.
-
-
34-39. -39. (canceled)
-
40. A transgenic organism, which includes a transgene which encodes an EPOa-IgG fusion protein.
-
41-45. -45. (canceled)
-
46. A pharmaceutical composition having a therapeutically effective amount of an EPOa-IgG fusion protein.
-
47. A method of treating a subject in need of erythropoietin comprising administering a therapeutically effective amount of an EPOa-IgG fusion protein to the subject.
-
48-54. -54. (canceled)
- 55. A method for making an EPOa-IgG fusion protein in a cultured cell comprising supplying a cell which includes a nucleic acid which encodes an EPOa-IgG fusion protein, and expressing the EPOa-IgG fusion protein from the nucleic acid, thereby making the EPOa-IgG fusion protein.
-
56. (canceled)
-
57. An EPOa-IgG fusion protein, wherein both the EPOa moiety and the human IgG moiety of the fusion protein are altered such that any site that serves as a site for glycosylation is altered such that it cannot serve as a site for glycosylation in the EPOa-IgG fusion protein, making the entire EPOa-IgG fusion protein non-glycosylated.
-
58-60. -60. (canceled)
Specification